Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2009;119:931-939
Published online before print February 9, 2009, doi: 10.1161/CIRCULATIONAHA.108.816181
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
119/7/931    most recent
CIRCULATIONAHA.108.816181v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mora, S.
Right arrow Articles by Ridker, P. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mora, S.
Right arrow Articles by Ridker, P. M
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Lipids
Right arrow Epidemiology
Right arrow Lipid and lipoprotein metabolism
Right arrowRelated Article

(Circulation. 2009;119:931-939.)
© 2009 American Heart Association, Inc.


Epidemiology

Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women

Samia Mora, MD, MHS; James D. Otvos, PhD; Nader Rifai, PhD; Robert S. Rosenson, MD; Julie E. Buring, ScD; Paul M Ridker, MD, MPH

From the Divisions of Preventive Medicine (S.M., J.E.B., P.M.R.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; LipoScience, Inc (J.D.O.), Raleigh, NC; University of Michigan Medical Center (R.S.R.), Ann Arbor, Mich; and Children’s Hospital (N.R.), Boston, Mass.

Correspondence to Samia Mora, MD, Brigham and Women’s Hospital, 900 Commonwealth Ave E, Third Floor, Boston, MA 02215. E-mail smora{at}partners.org

Received August 20, 2008; accepted December 15, 2008.

Background— Nuclear magnetic resonance (NMR) spectroscopy measures the number and size of lipoprotein particles instead of their cholesterol or triglyceride content, but its clinical utility is uncertain.

Methods and Results— Baseline lipoproteins were measured by NMR in 27 673 initially healthy women followed up for incident cardiovascular disease (n=1015) over an 11-year period. After adjustment for nonlipid risk factors, hazard ratios and 95% confidence intervals for the top versus the bottom quintile of NMR-measured lipoprotein particle concentration (measured in particles per liter) were 2.51 (1.91 to 3.30) for low-density lipoprotein (LDLNMR), 0.91 (0.75 to 1.12) for high-density lipoprotein (HDLNMR), 1.71 (1.38 to 2.12) for very low–density lipoprotein (VLDLNMR), and 2.25 (1.80 to 2.81) for the LDLNMR/HDLNMR ratio. Similarly adjusted results for NMR-measured lipoprotein particle size (measured in nanometers) were 0.64 (0.52 to 0.79) for LDLNMR size, 0.65 (0.51 to 0.81) for HDLNMR size, and 1.37 (1.10 to 1.70) for VLDLNMR size. Hazard ratios for NMR measures were comparable but not superior to standard lipids (total cholesterol 2.08 [1.63 to 2.67], LDL cholesterol 1.74 [1.40 to 2.16], HDL cholesterol 0.52 [0.42 to 0.64], triglycerides 2.58 [1.95 to 3.41], non-HDL cholesterol 2.52 [1.95 to 3.25], total/HDL cholesterol ratio 2.82 [2.23 to 3.58]) and apolipoproteins (B100 2.57 [1.98 to 3.33], A-1 0.63 [0.52 to 0.77], and B100/A-1 ratio 2.79 [2.21 to 3.54]). Essentially no reclassification improvement was found with the addition of the LDLNMR particle concentration or apolipoprotein B100 to a model that already included the total/HDL cholesterol ratio and nonlipid risk factors (net reclassification index 0% and 1.9%, respectively), nor did the addition of either variable result in a statistically significant improvement in the c-index.

Conclusions— In this prospective study of healthy women, cardiovascular disease risk prediction associated with lipoprotein profiles evaluated by NMR was comparable but not superior to that of standard lipids or apolipoproteins.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2009 119: 909-911. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Musunuru, M. Orho-Melander, M. P. Caulfield, S. Li, W. A. Salameh, R. E. Reitz, G. Berglund, B. Hedblad, G. Engstrom, P. T. Williams, et al.
Ion Mobility Analysis of Lipoprotein Subfractions Identifies Three Independent Axes of Cardiovascular Risk
Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1975 - 1980.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Ala-Korpela, P. Soininen, and M. J. Savolainen
Letter by Ala-Korpela et al Regarding Article, "Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women"
Circulation, October 27, 2009; 120(17): e149 - e149.
[Full Text] [PDF]


Home page
CirculationHome page
S. Mora, J. E. Buring, P. M. Ridker, N. Rifai, J. D. Otvos, and R. S. Rosenson
Response to Letter Regarding Article, "Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women"
Circulation, October 27, 2009; 120(17): e150 - e150.
[Full Text] [PDF]


Home page
CirculationHome page
S. Mora
Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use
Circulation, May 5, 2009; 119(17): 2396 - 2404.
[Full Text] [PDF]